Vitiligo
☆ AI Dermatology — Free Service
2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
Non‑segmental vitiligo (ne‑segmentālais vitiligo)
Pirkstu vitiligo ir grūtāk ārstēt nekā citās vietās. Papildus tam, ka vitiligo ir kosmētiski neizskatīgs, tas ir normāls un nav lipīgs. Dermatoloģijā visefektīvākā ārstēšana ir fototerapija vai lāzerterapija (eksimērs) 2–3 reizes nedēļā vismaz 1 gadu. Ja finansiālu vai laika ierobežojumu dēļ nevarat bieži doties uz klīniku, varat izmēģināt mājas lietošanai apstiprinātu fototerapijas iekārtu.
Vitiligo uz rokas.
relevance score : -100.0%
ReferencesVitiligo ir izplatīta ādas slimība, kas izraisa baltus plankumus melanocītu zuduma dēļ. Jaunākie pētījumi liecina, ka tā ir autoimūna slimība. Lai gan tas bieži tiek uzskatīts par kosmētisku problēmu, tas var būtiski ietekmēt garīgo labsajūtu un ikdienas dzīvi. 2011. gadā eksperti atsevišķi no citiem klasificēja tipu ar nosaukumu segmental vitiligo.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Aktīviem vitiligo pacientiem ir vairākas terapijas iespējas, piemēram, sistēmiski glikokortikoīdi, fototerapija un sistēmiski imūnsupresanti. Stabilajiem vitiligo pacientiem var būt iespēja atbrīvoties no lokāliem kortikosteroīdiem, lokāliem kalcineirīna inhibitoriem, fototerapijas un transplantācijas procedūrām. Nesenie sasniegumi vitiligo pamatā esošo procesu izpratnē ir novedusi pie mērķtiecīgas terapijas izstrādes. Pašlaik JAK inhibitori ir visdaudzsološākie, piedāvājot labu panesamību un funkcionālus rezultātus, neskatoties uz latentu infekciju aktivizācijas risku un sistēmiskām blakusparādībām, kas raksturīgas citiem imūnsupresīviem līdzekļiem. Notiekošo pētījumu mērķis ir identificēt galvenos citokīnus, kas iesaistīti vitiligo attīstībā (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Šo citokīnu bloķēšana ir izrādījusies daudzsološa dzīvnieku modeļos un dažiem pacientiem. Turklāt tiek pētīta miRNA-based therapeutics un adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Nav zināma ārstēšana pret vitiligo. Tiem, kuriem ir gaiša āda, parasti ieteicams izmantot sauļošanās līdzekli un kosmētiku. Citas ārstēšanas iespējas var ietvert steroīdu krēmus vai fototerapiju.
○ Ārstēšana
#Phototherapy
#Excimer laser
#Tacrolimus ointment